Business Context and Reporting Period
This Form 6-K filing by AMBEV S.A. covers the period from March 1 to March 31, 2022. The report details consolidated transactions of securities and derivatives involving the company's Board of Directors, Management, and Fiscal Council, in compliance with Article 11 of CVM Instruction # 358/2002. The filing was signed on April 11, 2022.
Key Financial Metrics
This filing is a regulatory disclosure of insider trading activity and does not contain consolidated financial statements. Consequently, the following metrics are not provided in this document:
- Revenue
- Profit
- Cash flow
- Margins
- Debt
- Liquidity
The only financial data present relates to the volume and price of specific share and ADR transactions by insiders.
Material Changes and Insider Transactions
The filing reports significant changes in the equity holdings of the Board of Directors and Management during March 2022:
- Board of Directors:
- Acquisitions: Exercised options for 238,990 Common Shares at R$15.20 (Volume: R$3,632,648).
- Dispositions: Sold a total of 815,000 Common ADRs via JP Morgan between March 4 and March 28. Prices ranged from approximately R$13.78 to R$14.37. Total volume exceeded R$11 million.
- Net Position: Common Shares increased to 12,194,947; Common ADRs decreased to 0.
- Management:
- Acquisitions: Received 27,341 Restricted Shares and exercised options for 1,146,671 Common Shares (Volume: R$17,429,399) and 76,804 Common ADRs (Volume: R$1,167,421).
- Dispositions: Sold 1,500 Common Shares and 100,000 Common ADRs.
- Net Position: Common Shares increased to 6,760,995; Common ADRs decreased to 541,613.
- Fiscal Council: No transactions reported; holdings remained at 0.
Guidance, Outlook, and Risks
The filing text does not provide any management commentary, forward-looking guidance, outlook, risk factors, contingencies, or discussion of unusual items. The document is strictly a transactional report.
Investor Verification Checklist
- Verify the total volume of ADR sales by the Board of Directors (815,000 units) against market data for March 2022 to assess potential market impact.
- Confirm the exercise price of R$15.20 for options exercised by both the Board and Management against the prevailing market price on March 30, 2022.
- Review the final holdings to note that the Board of Directors completely liquidated their ADR position (0 remaining) while increasing their direct Common Share holdings.
- Check subsequent filings for the company's Q1 2022 financial results, as this 6-K does not contain operational performance data.